MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

NCT01425879 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

NIH

Sponsor class

Conditions

Advanced Adult Hepatocellular Carcinoma
Localized Non-Resectable Adult Liver Carcinoma
Recurrent Adult Liver Carcinoma
Recurrent Gallbladder Carcinoma
Stage IV Distal Bile Duct Cancer
Stage IV Gallbladder Cancer
Unresectable Extrahepatic Bile Duct Carcinoma
Unresectable Gallbladder Carcinoma

Interventions

DRUG: Akt Inhibitor MK2206
OTHER: Diagnostic Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)